Key Resources (listed chronologically, beginning with the most recent)
“Chart: Key Provisions of Proposals on Drug Price Negotiation, Inflation Rebates, and Medicare Part D Redesign.” Wynne Health Group. September 27, 2019. Available at http://allh.us/86fD.
“Looking Ahead: Policy Options for Addressing High Drug Prices.” Gustafsson, L. To The Point (blog). The Commonwealth Fund. July 30, 2019. Available at http://allh.us/vmhY.
“Use Real-World Data, Not International Reference Pricing, to Set US Drug Prices.” Axelsen, K. AEIdeas (blog). June 25, 2019. Available at http://allh.us/m4UQ.
“How Drug Prices Are Negotiated in Germany.” Robinson, J., Ex, P., and Panteli, D. June 13, 2019. To The Point (blog). The Commonwealth Fund. Available at http://allh.us/mYV8.
“Getting to the Root of High Prescription Drug Prices.” Waxman, H., Corr, B., and Martin, K. The Commonwealth Fund. July 2017. Available at http://allh.us/9vu4.
Additional Resources (listed chronologically, beginning with the most recent)
“Considerations for Expanding International Reference Pricing Beyond Medicare Part B.” Adler, L., Lieberman, S., Linke Young, C. et al. Health Affairs Blog. September 9, 2019. Available at http://allh.us/xRrd.
“Medicare Price Negotiation—Why Now…and How.” Frank, R. and Nichols, L. The New England Journal of Medicine. September 4, 2019. Available at http://allh.us/gy8Q.
“Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2019 Year-End Update.” Schondelmeyer, S. and Purvis, L. AARP Public Policy Institute. September 2019. Available at http://allh.us/qpDC.
“The Economics of Biologic Drugs.” Brill, A. and Ippolito, B. Health Affairs Blog. August 8, 2019. Available at http://allh.us/tcWY.
“Senate Finance Committee Proposes Reforms to Medicare and Medicaid Drug Policy.” O’Neill Hayes, T. American Action Forum. August 6, 2019. Available at http://allh.us/4BY8.
“What’s the Latest on Medicare Drug Price Negotiations?” Cubanski, J., Neuman, T., True, S., et al. Kaiser Family Foundation. July 23, 2019. Available at http://allh.us/C9rX.
“Setting the Record Straight on International Reference Pricing.” Haninger, K. The Catalyst (blog). Pharmaceutical Research and Manufacturers of America. July 16, 2019. Available at http://allh.us/x7VG.
“CMS’s International Pricing Model for Medicare Part B Drugs: Implementation Issues.” Lieberman, S. and Ginsburg, P. Health Affairs Blog. July 9, 2019. Available at http://allh.us/AeWR.
“Sending the Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less than Generics?” Dusetzina, S., Jazowski, S., Cole, A., et al. Health Affairs. July 2, 2019. Available at http://allh.us/TuVc.
“Reconciling the Seemingly Irreconcilable: How Much are We Spending on Drugs?” Kleinrock, M., Westrich, K., Buelt, L., et al. IQVIA Institute for Human Data Science and The National Pharmaceutical Council. July 2019. Available at http://allh.us/tA6w.
“Medicare Part D: Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization.” GAO Highlights. July 2019. Available at http://allh.us/YTdC.
“Here’s How We Can Control Drug Costs While Spurring Innovation.” Goldman, D. The Hill. June 14, 2019. Available at http://allh.us/ra8G.
“Prescription Drug Pricing: Striking the Right Balance.” Haislmaier, E. and Owcharenko Schaefer, N. The Heritage Foundation. June 7, 2019. Available at http://allh.us/xGbk.
“Six Drug Pricing Models Have Emerged to Improve Product Access and Affordability.” Comer, B. PwC. May 29, 2019. Available at http://allh.us/cqpm.
“Improving Drug Pricing Transparency and Lowering Prices for American Consumers.” Holtz-Eakin, D. American Action Forum. May 21, 2019. Available at http://allh.us/PFCh.
“Is Arbitration an Answer for High Drug Prices?” Rother J. To The Point (blog). The Commonwealth Fund. May 3, 2019. Available at http://allh.us/KvR8.
“Pharmacy Benefit Managers and Their Role in Drug Spending.” The Commonwealth Fund. April 22, 2019. Available at http://allh.us/nj4h.
“Biologics Are Natural Monopolies: Why Biosimilars Do Not Create Effective Competition.” Atteberry, P., Bach, P., Ohn, J., et al. Health Affairs Blog. April 15, 2019. Available at http://allh.us/VkdU.
“The Gross-to-Net Bubble Reached a Record $166 Billion in 2018.” Fein, A. Drug Channels. April 3, 2019. Available at http://allh.us/BxFJ.
“A Closer Look at International Reference Pricing for Prescription Drugs.” Capretta, J. RealClearPolicy. March 29, 2019. Available at http://allh.us/p4fB.
“Single-Payer Drug Pricing in a Multiplayer Health System: Does Germany Offer a Model for the US?” Robinson, J., Ex, P., and Panteli, D. Health Affairs Blog. March 22, 2019. Available at .
“Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid.” Congressional Budget Office. March 2019. Available at http://allh.us/UK3V.
“What Medicare Can Learn from Other Countries on Drug Pricing?” Roy, A. The Foundation for Research on Equal Opportunity. January 11, 2019. Available at http://allh.us/hAC3.
“The Contribution of New Product Entry Versus Existing Product Inflation in the Rising Cost of Drugs.” Hernandez, E., Good, C., and Gellad, W., et al. Health Affairs. January 2019. Available at http://allh.us/qkMP.
“Balancing Innovation and Competition in the Biologics Marketplace.” Korn, D. The Catalyst. Pharmaceutical Research and Manufacturers of America. October 11, 2018. Available at http://allh.us/HCrk.
“Understanding the Drivers of Drug Expenditures in the U.S.” QuintilesIMS Institute. September 2017. Available at http://allh.us/aUx4.
“Rising Costs for Patented Drugs Drive Growth of Pharmaceutical Spending in the U.S.” Blue Cross Blue Shield. The Health of America Report. May 3, 2017. Available at http://allh.us/gCTk.
“Fact Sheet: How Much Money Could Medicare Save By Negotiating Prescription Drug Prices?” Committee for a Responsible Federal Budget. April 11, 2016. Available at http://allh.us/4Kqx.